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1. Introduction 
Apathy is one of the most common neuropsychiatric complications of neurodegenerative 
disorders such as Alzheimer (AD) and Parkinson disease (PD).  Apathy can be broadly defined 
as a clinical syndrome characterised by a change from baseline in three key domains: level of 
interest, level of initiative and emotional reactivity. It is one of the most under-diagnosed and 
poorly managed aspects of the neurodegenerative disorders. In PD particularly, the 
consequences of apathy may be significant and may impact negatively on long-term 
prognosis, exacerbate the motor and physical aspects of the disease, add to carer burden and 
stress, be associated with greater functional decline and disability, and impair quality of life 
(QOL). This chapter will outline these various outcomes and their relation to apathy in PD.   
2. Background to apathy in PD 
The prevalence of apathy in PD has been reported as ranging from about 17% to over 40% 
(Pluck and Brown, 2002). This wide range is likely a result of differences in populations 
studied (e.g. community versus clinic), types of apathy rating scales used, and discrepancies 
in, or lack of, the use of validated diagnostic criteria.  In a cross-sectional validation study of 
newly proposed diagnostic criteria for apathy, the frequency of apathy in the PD subgroup 
was 27% (Mulin et al., 2011).  
The definition of apathy has evolved over the past few years as the multi-dimensional 
nature of the syndrome is increasingly being recognised. A common conceptualisation of 
apathy, as proposed by Starkstein et al. (2001) among others, is that it constitutes a lack or 
reduction of goal-directed behaviour, as manifested in the dimensions of: (1) loss of or 
diminished initiative; (2) loss of or diminished interest; and (3) diminished or blunted 
emotions.  The syndrome of apathy, while very common in neurodegenerative disorders, 
may also occur in other medical, neurologic or psychiatric conditions.  The diagnostic 
criteria for apathy have followed the definition. Most recently, an international task force 
proposed a new set of criteria which have now been validated in several conditions, 
including AD and PD (Robert et al. 2009; Mulin et al., 2010).  According to these criteria, a 
diagnosis of apathy can be made in the presence of four or more weeks of a loss of or 
reduction in motivation in at least two of three proposed apathy dimensions of emotional 
reactivity, interest and initiative. This change in behaviour should be sufficient to cause 
clinically significant impairment in functioning in various spheres.   
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Aside from diagnostic criteria, apathy can also be rated using a number of different validated 
apathy rating scales.  These scales were reviewed by the Movement Disorder Society (MDS) 
and the recommendation for PD was that the Apathy Scale (AS) (Starkstein et al., 1992) or the 
Apathy Evaluation Scale (AES; clinician version, AES-C) (Marin, 1991) were the most robust 
scales for use in PD (Leentjens et al., 2008).  PD-specific apathy rating scales which have 
recently been developed include the Apathy Inventory (AI) (Robert al., 2002), which can be 
either patient- or informant-rated, as well as the Lille Apathy Scale (LARS) (Sockeel et al., 
2006). The LARS is a 33-item scale comprised of nine domains underscoring the apathy 
syndrome. Scores can range from an optimal score (no apathy) of +36 to the most severe score 
of -36, and the cut-off score for moderate apathy is -16.  Principal component analysis of data 
derived from a study of 159 PD participants (51 with apathy as per the LARS cut-off) revealed 
a four-factor solution describing apathy dimensions. These were: intellectual curiosity, action 
initiation, emotion and self-awareness (Dujardin et al., 2007). Gallagher et al. (2008) used the 
LARS to determine how useful the Unified Parkinson’s Disease Rating Scale, Part I (UPDRS) 
(Fahn & Elton, 1987) is as an apathy screening and diagnostic instrument by rating both scales 
in 74 PD sufferers. Using the LARS cut-off, 20% of the sample had apathy and they found that 
the UPDRS apathy item was sensitive (73%) in detecting apathy in PD but did not have 
sufficient diagnostic quality. Finally, the apathy domain of the informant-based 
Neuropsychiatric Inventory (NPI) (Cummings et al., 1994), has also been validated for 
identifying apathy, as either a “present/absent”, or in terms of magnitude (frequency x 
severity). On this scale, a domain score for magnitude of symptoms of ≥ 4 indicates “clinically 
significant” pathology although no clear cut-off score for apathy per se has been established.  
A clinician-rated version of the NPI (NPI-C) is currently being developed and may be useful in 
the assessment and diagnosis of apathy (de Medeiros et al., 2010).  
The underlying pathophysiology of apathy is related to specific disease-related degenerative 
brain changes that impact on motivation, and possibly, reward pathways. In particular, 
deficits in the frontal-subcortical circuit involving the anterior cingulated cortex (ACC) are 
likely to result in an apathy syndrome, or in specific dimensions of the syndrome (Robert et al., 
2009; Devinsky et al., 1995). Neurotransmitter deficits which may play a role in apathy include: 
dopamine, which is important in reward and motivation; serotonin (5-HT), which may also 
have a role in PD-related depression in PD; and acetylcholine, a key neurotransmitter whose 
loss is related to dementia in PD (Czernecki et al., 2002; Leentjens et al., 2006).  
The syndrome of apathy may occur as a sole behavioural complication of PD, or, as is 
frequently the case, may be co-morbid with other psychiatric complications such as depression 
or anxiety (Pluck and Brown, 2002; Aarsland et al, 1999).  In our own cross-sectional study of a 
sample of 99 PD participants without dementia, the proportion of the 26 participants with 
apathy (on AES-C) who also experienced moderate to severe depression (Hospital Anxiety 
and Depression Rating Scale (HADS), depression sub-score ≥ 11) was 45%, which was 
significantly higher than in the PD participants with no apathy. Furthermore, HADS anxiety 
ratings were also significantly higher in those with apathy compared to those with no apathy 
(Leroi et al., 2009). The co-occurrence of apathy and depression in PD may be a diagnostic 
challenge, however, it is important to distinguish these syndromes in order to ensure that 
management strategies for depression, which are commonly prescribed, do not worsen or 
leave apathy symptoms untreated.  If properly validated scales for apathy and depression are 
used in the diagnosis, it is possible to parse out the diagnostic entities with a degree of 
accuracy (Marin et al., 1993; Dujardin et al., 2007).   
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3. Impact of apathy on prognosis in PD 
The question of whether the presence of apathy in PD impacts on prognosis is an important 
one since it has implications for early and robust detection and management of apathy. 
Unfortunately, very few long-term prospective studies have examined this question and the 
handful of cross-sectional studies linking apathy to disease severity are not entirely 
adequate to address the question of causation. Nonetheless, a few shorter-term follow-up 
studies have been done, in PD as well as AD, and suggest that the presence of apathy may 
have negative implications for the disease course, particularly once dementia is already 
established. Apathy in PD may also as a risk factor for the conversion into dementia from 
the non-demented state (Starkstein et al., 2006; Robert et al., 2006a; Dujardin et al. 2009). One 
of the only PD studies to address this question longitudinally is a study of apathy in a 
cohort of 40 non-demented PD patients who were followed up for a median of 18 months. 
Those with apathy (n=20) had a higher rate of conversion to dementia in PD over this period 
compared to those who had no apathy (n=20) at the start of the study (Dujardin et al., 2009). 
These findings are consistent with a longer study in AD patients for up to four years which 
revealed that apathy sufferers had a more severe overall prognosis and declined more 
rapidly compared to those without apathy (Starkstein et al., 2006). Another study, of shorter 
duration, found that in those with apathy and the amnestic form of mild cognitive 
impairment (MCI) converted to dementia in AD at a higher rate after one year compared to 
those without apathy (Robert al., 2006a).  
4. Impact of apathy on the physical aspects of PD 
PD is primarily a movement disorder affecting gait, speed and flexibility of movement. As 
the disease progresses, these symptoms become worse rendering the PD sufferer less active 
and increasingly prone to the complications of immobility. Furthermore, other, non-motor 
aspects of the disease such as postural instability, swallowing difficulties, bladder and 
bowel problems, cognitive impairment and depression may also contribute to a greater 
disease burden and increase the risk of developing medical complications. If apathy is 
present as well, effects of both the motor and the non-motor aspects of the disease may be 
exaggerated. In particular, the apathy dimensions of lack of initiative and interest may result 
in the PD sufferer withdrawing from their usual physical activities and hobbies, including 
activities of daily living and becoming increasingly sedentary. This may exacerbate existing 
problems such as constipation, and may also lead to secondary physical complications 
including urinary and respiratory infections, deep vein thrombosis and increased frailty.  
Loss of appetite, weight loss and poor nutritional status may also be associated with the 
presence of apathy and these conditions also add risk of developing medical complications 
and hastening decline (Benoit et al, 2008).  
5. Impact of apathy on cognitive function in PD 
Cognitive impairment in PD can broadly be categorised into dopaminergically-driven 
executive-type cognitive changes, which appear early on in the course of the disease, and 
more widespread, cholinergically-driven dementia-type cognitive changes, which occur as 
the disease advances (Williams-Gray et al., 2007). Executive dysfunction, including 
impairments in planning, verbal fluency, working memory, and attention, may progress to 
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the point whereby functional abilities are affected. At this stage, it can be considered “mild 
cognitive impairment” (MCI) in PD.  The more widespread cognitive impairments that lead 
to a full dementia syndrome typically appear after about 11 years of PD and may occur in 
over 80% of PD sufferers if they live with the disease for long enough (Hely et al., 2008). 
A characteristic aspect of cognitive impairment in PD is “bradyphrenia”, or slowness of 
thinking, which may be underscored by various aspects of the disease, including deficits in 
attention and interest, fatigue, slowness of thinking, poor persistence in tasks, mild memory 
problems, as well as apathy. Specifically, the lack of initiative and interest, which are key 
dimensions of PD-related apathy, may contribute to the development of bradyphrenia.  
The cognitive changes that frequently accompany apathy syndromes are gradually being 
understood, however there have only been a few studies specifically examining this issue in 
PD. Whether these cognitive changes are the consequence or an impact of apathy, rather than 
apathy being a behavioural manifestation of the cognitive changes is not entirely clear (Duffy 
and Campbell, 1994). At best this relationship can be considered “bidirectional”.  Some of the 
studies examining cognitive changes in apathy in PD have used such tools as the Mini-mental 
State Exam (MMSE) (Folstein et al., 1975). The overall finding are that those with apathy are 
more cognitively impaired globally compared to those who do not have apathy (e.g. Landes et 
al., 2001; Starkstein et al., 2001, 2005; Aarsland et al., 2001; Senanarong et al., 2005). Studies 
using more specific neuropsychological test batteries reveal a strong association between 
apathy and frontal-type cognitive functions, even in the non-demented state. In our own cross-
sectional study of a cohort of 99 non-demented PD sufferers, 46%of the variance predicting 
working memory impairment, an aspect of frontal-executive dysfunction, was accounted for 
by the presence of apathy, as well as older age and the presence of motor complications 
(Andrews et al., 2009).  Working memory deficits in apathy in PD are of particular interest 
since both these functions may be underpinned by deficits in the ACC. In addition to working 
memory deficits, this same study also found significantly greater impairments in global 
cognitive impairment, as per the MMSE, as well as verbal fluency, even when accounting for 
differences in age, age on onset and duration of disease, and depression and anxiety.  
Interestingly, although attentional shift was initially worse in the apathy group, this difference 
was no longer evident once the co-variates were accounted for.  These findings are supported 
by studies of cognitive impairment in AD and MCI, which have also found significantly worse 
word list learning, verbal fluency, set shifting and naming in those with apathy compared to 
those without apathy (Kuzis et al., 1999; Sperry et al., 2001; Robert et al., 2006b; McPherson et 
al., 2002; Pluck and Brown, 2002; Starkstein et al., 1992).    
6. Impact of apathy on quality of life in PD 
Measurements of the subjective experience of living with a chronic, neurodegenerative 
disease have increasingly become a focus of clinical and research interest in PD. The concept 
of “quality of life”, or, more accurately, “health-related quality of life” (Hr-QOL) is a 
multidimensional construct embodying aspects of cognitive, emotional and physical 
functioning (Schrag, 2000). Several studies have used Hr-QOL scales to assess the impact of 
PD on individuals. These have shown that PD patients generally score lower than age-
matched controls with other diseases and that key factors associated with poor Hr-QOL 
include depression, social isolation, physical functioning,  sleep impairment, pain and 
discomfort, amongst other factors (Schrag, 2006). Depression in particular is an important 
factor determining Hr-QOL in PD, and this would suggest that a behavioural syndrome 
such as apathy, which is closely linked to depression, would also impact on this outcome. 
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6.1 PD study of apathy and quality of life 
To date, one of the only studies directly examining the impact of apathy on Hr-QOL in PD 
is our own cross-sectional study of 97 non-demented community dwelling PD sufferers 
(Leroi et al., 2011a) who were assessed with the Parkinson’s Disease Quality of Life Scale-
8 item version (PDQ-8)(Jenkinson et al., 1997), which is a well-validated abbreviated 
version of the PDQ-39 (Peto et al., 1995).  This study found that in those without frank 
dementia in PD, lower self-reported Hr-QOL was associated with less cognitive 
impairment and younger age, rather than the profile typical of those with apathy, namely, 
older age and more cognitive impairment (Leroi et al., 2011a).  These findings can be 
explained in that the younger and more active the PD sufferer is, the greater the impact of 
a diagnosis of a chronic degenerative disease may be. In contrast, those who are older, no 
longer working, and who may have lower expectations of life, may be less affected in 
terms of HRQoL. Interestingly, these findings are supported by a study of AD sufferers in 
care homes who had apathy. It found that in those with apathy, self-reported QOL was 
lower in those with less cognitive impairment, based on MMSE scores (Gerritson et al., 
2005).  
Data from the PD study mentioned above (Leroi et al., 2011a) were further analysed in order 
to compare “low” and “high” Hr-QOL in PD using the median split method.  The median 
score on the PDQ-8 was 20.8. Those who scored above this median (n=48) were considered 
as to have poorer Hr-QOL (higher PDQ-8 score is worse Hr-QOL), and those who scored 
below this median (n=51) were considered as having better Hr-QOL. Table 1 shows a 
comparison of the mean scores across various demographic and clinical factors. From this 
analysis, it was clear that “level of motivation” or apathy as determined by the AES-C score 
differed between the two groups, with significantly higher apathy scores (AES-C) in the 
“high” PDQ-8 group.  This comparison also revealed that those who were in the “high” 
PDQ-8 group (worse Hr-QOL) were no different in age to the low group, but differed 
significantly on several disease variables, including the “high” group having younger onset 
of disease, longer duration and more motor complications, in the form of dyskinesias, 
“on/off” phenomena and dystonias.  Psychiatrically, the two groups differed, with higher 
anxiety, depression and overall psychiatric burden scores, the latter as reflected by the NPI 
“total” score, in the “high” scoring group.  Cognitively, the two groups did not differ on 
global cognition (MMSE total), attention (serial 7’s; Trail Making Test-B), short-term 
memory (5 minute recall from the MMSE) or verbal fluency (FAS test), however, as is 
consistent with Leroi et al. (2011a), the “high” group were significantly better than the “low” 
group on measures of working memory (n-back). 
The above findings, however, contrast with other studies in PD, in which more severe levels 
of cognitive impairment or dementia, depression, and more advanced disease stage are 
associated with worse levels of self-reported Hr-QOL (Schrag 2006). The impact of disease 
variables may depend on stage of disease, with advanced disease and the presence of 
dementia having a greater impact compared to early disease (Schrag 2006).   Indeed, these 
are the conditions that are associated with more severe and more prevalent apathy 
syndromes.  It is possible that the presence of dementia may alter the impact of apathy on 
self-reported Hr-QOL due to apathy’s effect on insight and the ability to reflect on 
experiences affecting the self.  Our own data found that in comparing PDQ-8 in a cohort of 
PD-apathy sufferers  (NPI ≥ 4) without cognitive impairment  (n=24) to those with PDD and 
apathy (n=9), the PDD group had worse Hr-QOL (mean PDQ-8 in PD, 23.26 (SD 9.51); mean 
PDQ-8 in PDD, 34.02 (SD 12.67); t=-2.64, p=.01).  
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Patient measures 
(n=99) 
Low PDQ-8
(better Hr-
QOL) 
(n=51)
High PDQ-8
(worse Hr-
QOL) 
(n=48)
Statistic
(t test or 
Mann-
Whitney U)
Significance 
(p-value) 
 Mean (SD)  
Apathy Evaluation 
Scale –Clinicians’ 
version (total score)
26.92 (12.38) 33.30 (15.68) -2.24 .03 
Demographic factors:
Age at assessment 
(years) 
64.51 (9.67) 62.39 (11.46) 0.99 .33 
Clinical factors: 
Unified PD Rating 
Scale: motor 
subscale 
27.00 (12.10) 30.79 (11.40) -1.55 .12 
Unified PD Rating 
Scale: 
complications of 
therapy subscale
2.37 (2.56) 5.15 (3.48) U=589.50 <.001 
Duration of PD 
(months) 
82.47 (52.35) 110.35(75.09) -2.14 .04 
Age of onset of 
motor symptoms
57.71 (11.05) 52.78 (11.83) 2.12 .04 
Psychiatric measures:
Hospital Anxiety & 
Depression Rating 
Scale- depression 
subscore 
5.02 (3.56) 7.67 (3.65) U=609.50 <.001 
Hospital Anxiety & 
Depression Rating 
Scale-  anxiety 
subscore 
4.59 (3.62) 8.15 (4.38) U=704.50 <.001 
Neuropsychiatric 
Inventory total 
8.12 (11.09) 15.13 (13.99) U=743.50 .002 
Cognitive measures:
MMSE Serial 
sevens 
4.27 (1.00) 4.09 (1.33) 0.79 .43 
MMSE 5-minute 
recall 
2.49 (0.83) 2.48 (0.86) 0.07 .95 
Trails B error score 5.53 (9.31) 7.66 (10.39) -1.05 .30 
n-back 16.83 (3.51) 15.02 (3.62) 2.43 .02 
FAS 40.84 (14.06) 41.17 (12.44) -0.12 .90 
Table 1. Comparison of high- and low-PDQ-8 groups across various demographic and 
clinical variables in the   PD participant groups.  
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7. Impact of apathy on disability in PD 
The notion of “disability” in PD is increasingly recognised as being important however 
there is almost no literature on the specific association between apathy and disability in 
PD.  Disability, like quality of life or carer burden, is a multidimensional construct, likely 
underpinned by a variety of different factors, both generic and PD-specific. The general 
definition of “disability” as defined by the “Americans with Disabilities Act of 1990 is "a 
physical or mental impairment that substantially limits one or more major life activities" 
(http://www.ada.gov/cguide).  With regards to PD, “disability” loosely refers to 
“functional impairment” and is most commonly associated with the core aspects of the 
disease, namely, severity of motor impairments (tremor, instability, rigidity, 
bradykinesia).  Non-motor aspects of PD have also been shown to be key contributors to 
overall functional impairment, or disability. In particular, some studies have shown that 
the presence of or severity of depression is associated with increased disability 
(Weintraub et al., 2004; Holroyd et al., 2005). One of the most comprehensive studies on 
this topic was by Weintraub et al. (2004). This study found that using a bivariate analysis, 
the key associated features with disability were the presence of psychosis, depression 
(presence and severity), age, duration  of PD, cognitive impairment, apathy, sleepiness 
and aspects of motor impairment. Assessing these factors with a multivariate analysis, 
37% of the variance in UPDRS ADL score was accounted for by severity of depression and 
worsening cognition, and 54% of the variance in Schwab-England score was accounted for 
by the same two factors plus increasing severity of PD.  The limitation of this study was 
that it was undertaken in a mostly male, veteran population in the USA and did not have 
a control group of comparable motor severity in PD. Hence, the generalisability to the 
general PD population is limited.  To date there have been relatively few studies 
investigating the specific impact of apathy on disability in PD, however, it is likely that  
apathy-induced disability has a further impact by increasing carer burden and levels of 
distress. 
7.1 PD study of apathy and disability 
In PD, the most robust way to measure disability is using a PD-specific activities of daily 
living (ADL) scale from the UPDRS, as well as a more general disability scale, the Schwab-
England scale (Schwab & England, 1969). Disability captures the notion that the ability to 
undertake ADL is an important measure of disease severity and may not be dependent on 
duration of disease or stage according to the Hoehn-Yahr scale.  The UPDRS ADL 
subscale is a 13-item scale that rates degree of ability to carry out daily tasks such as 
dressing and using a cutlery on a scale of 0-4 per item. It has a range of 0-52, with higher 
scores indicating greater impairment.  It was designed specifically for assessing those 
with a diagnosis of PD and encompasses such items as the ability to eat and drink, move, 
toilet, dress, undertake hygiene routines, and communicate. The Schwab-England scale 
rates ADL ability on a scale of 0-100% with 100% being completely independent and with 
no disability. This scale is a useful global measure of independence and performance on 
ADL. 
Using the UPDRS ADL scale, as well as the Schwab-England scale, we undertook a cross-
sectional study of 99 non-demented PD sufferers with apathy, as determined by the AES-C 
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(Leroi et al., 2011a). These participants were consecutively recruited from neurology clinics 
in the UK and all met criteria for idiopathic PD. We found that disability on these measures 
was significantly higher in those with both apathy and PD (n=26) compared to those 
without apathy and PD (n=73). Mean disability ratings are shown Table 2. Furthermore, 
apathy was strongly and significantly associated with higher levels of disability rated on 
both these scales (UPDRS-ADL, rho=0.36; p<0.001; Schwab-England, rho=-0.55; p<0.001). In 
a subsequent multivariate regression analysis, apathy, together with later stage of disease 
and more cognitive impairment, accounted for 56% (p<.001) of the variance predicting 
disability. 
 
 Mean (SD)  
 Apathy  (n=26) 
Control 
(n=73) 
Statistic 
Unified PD 
Rating Scale: 
ADL subscale 
18.23 
(4.10) 
13.35 
(4.97) 
t=4.50;  p<.001 
Schwab-
England scale 
63.46 
(12.39) 
82.00 
(9.26) 
t=-8.93; p<.001 
Table 2. Disability ratings compared between the two non-demented PD groups: with and 
without apathy 
Further analysis of these data using the median split method was undertaken to explore the 
relationship of various demographic and clinical (motor, psychiatric and cognitive) factors 
between those with high levels of disability (mean UPDRS ADL score equal to or above the 
median cut-off of 15; n=53) and those with low levels of disability (mean UPDRS ADL score 
below the median cut-off of 15; n=46). Table 3 shows the comparison between the two 
groups of the mean scores across various factors.  The mean apathy score (AES-C) was 
significantly higher in the “high” disability group (p=.004) in spite of there being no 
significant difference in age and several disease variables such as duration of disease, age of 
onset and dopaminergic load. However, the more disabled group did have worse motor 
scores (higher UPDRS motor score)(p<.001), worse motor complications (higher UPDRS 
complications of therapy score)(p=.03), and more severe stage of disease (Hoehn-Yahr 
score)(p=.001).  
Interestingly, and in contrast to previous findings in the literature, there was no difference 
between groups on level of self-rated depression and anxiety, as assessed by the HADS. 
With regards to cognitive variables, there was no difference in complex attention (serial 7’s), 
and short-term memory (5 minute recall from the MMSE).  In contrast, there was greater 
impairment in verbal fluency (FAS test)(p=.04) and time for attentional shift/visual 
scanning (Trail-making Test-B time)(p=.006) in the high disability group. Finally, as 
expected, this group was also significantly more impaired on working memory (n-back; 
p=.001).  These findings underscore the significant impact that apathy and cognitive 
impairment have on disability in PD. 
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Participant 
measures 
(n=99) 
Low ADL
Mean (SD) 
(n=53)
High ADL
Mean (SD) 
(n=46)
Statistic
(t test or Mann-
Whitney U)
Significance 
(p-value) 
 Mean (SD)
Measure of  motivation:
Apathy 
Evaluation Scale-
Clinicians’ 
version 
26.17 (12.07) 33.78 (15.63) U=817.00 .004 
Demographic factor:
Age at 
assessment 
(years) 
62.04 (10.50) 64.65 (10.78) t=-1.22 .23 
Disease factors:
Unified PD 
Rating Scale:  
motor 
24.00 (10.10) 34.47 (11.27) t=-4.72 <.001 
Unified PD 
Rating Scale: 
complications of 
therapy 
2.92 (2.74) 4.48 (3.71) U=917.00 .03 
Duration of PD 
(months) 
84.87 (59.96) 105.83 (69.61) t=-1.61 .11 
Age of onset of 
motor symptoms 
(years) 
54.92 (11.41) 55.54 (12.03) t=-0.26 .79 
Hoehn-Yahr 
scale 
2.09 (0.67) 2.55 (0.65) t=-3.44 .001 
Levodopa  
equivalent 
daily dose (mg) 
798.19 (641.38) 821.10 (507.66) U=1132.00 .54 
Psychiatric measures:
Hospital Anxiety 
& Depression 
Scale: depression 
subscore 
5.81 (4.13) 6.78 (3.37) U=979.00 .12 
Hospital Anxiety 
& Depression 
Scale: anxiety 
6.73 (4.73) 5.76 (3.84) U=1089.50 .45 
Cognitive measures:
Mini-mental 
State Exam 5-
minute recall 
2.55 (0.77) 2.41 (0.91) U=1133.00 .47 
Trail Making 
Test-B time to 
complete (sec) 
134.41 (86.64) 175.46 (88.31) U=793.56 .006 
Trail Making 
Test- B error 
score 
5.12 (9.02) 7.89 (10.49) U=956.50 .13 
n-back 17.06 (3.38) 14.55 (3.55) t=3.48 .001 
FAS 43.47 (14.71) 38.22 (10.58) t=2.01 .04 
Table 3. Comparison of high- and low-disability (ADL) groups across various demographic 
and clinical  variables in the PD participant groups. 
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8. Impact of apathy on carer burden in PD 
Caring for someone with a chronic, prolonged and degenerative disorder such as PD can be 
associated with significant stress, strain and perceived burden in the carer.  This is similar to 
the well-established effects that such caring may have on informal carers of any chronic and 
serious disease, and it has been shown that mortality of these carers is actually increased if 
emotional or mental strain results (Schulz and Beach, 1999).  In PD, the complexity of the 
disease, which involves not only physical, but also cognitive and behavioural impairment, 
means that the caring role is even more challenging. Carers in PD have to be responsible for 
managing the household, the family finances, and other activities of daily living, as well as 
the physical care needs of the patient.  These responsibilities generally increase as the 
disease progresses, and one study showed that while in the earlier stages of PD the carer 
performed an average of 11 care-related activities per day, in the later stages of PD, this 
increased to up to 30 per day (Carter et al., 1998).  The manifestations of such carer burden 
in PD carers include depression, limitations in social life and low quality of life (Schrag et 
al., 2006).  
Patient factors that have been shown to be associated with carer burden and stress include: 
severity of motor functioning; presence of mental dysfunction, particularly depression and 
cognitive impairment (Aarsland et al., 1999); and functional status (Martinez-Martin et al., 
2007; Aarsland et al., 1999). However, the specific impact on carer burden of apathy has not 
been as well studied other than in those with significant cognitive impairment and dementia 
(Aarsland, 2007). 
8.1 PD study of apathy and carer burden 
Over the past few years, the issue of assessing carer burden and distress has been 
recognized as being much more complicated than previously appreciated. Since PD is a 
long-term condition which impacts on multiple facets of functioning, it follows that the 
effect on carers cannot be easily modelled. However, a simplified and commonly used 
method for assessing subjective carer burden is using a well-validated scale, the 29-item 
Zarit Burden Interview (Zarit et al., 1980). In this questionnaire, responses range from 0 
(never) to 4 (nearly always) and it rates the impact on the carer’s physical, emotional and 
socioeconomic status. Higher scores reflect greater carer burden.  Our own study used a 
modified version (22-item) of this measure to examine the impact of apathy on carer burden 
in a cohort of 71 non-demented PD patients and their carers (Leroi et al., 2011b).  The carers 
in this group were mostly male (60.6%) and had a mean age of 62.7 (SD 10.9) years. They 
had known the PD sufferer for a mean length of time of 39.8 (SD 14.4) years. The mean ZBI 
score in the group overall was 23.8 (SD 14.0) years.  Apathy was defined in the PD sufferer 
as being a score of ≥14 on the modified Apathy Scale (Starkstein et al., 1992). Findings from 
this study revealed that carer burden in those with apathy was significantly greater 
compared to those without apathy (p=.004). This was supported by the finding of a strong 
correlation between level of apathy and carer burden (rho=0.41; p=<.001). 
9. Conclusion 
The discussion above has highlighted the significant negative impact that the presence of 
apathy can have in PD, whether or not dementia is present. In particular, apathy can have 
an adverse effect on prognosis of the disease, cognitive and physical functioning, quality of 
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life, disability and carer burden. However, this evidence has been gained mostly from cross-
sectional studies which are limited in their ability to determine causality between apathy 
and these various outcomes. Longer, more detailed prospective studies are needed to 
examine these issues further in order to emphasize the need for more robust detection of 
and intervention into apathy in order to offset the negative outcomes.  
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